SF) stimulation was analysed by ELISA. FAO was inhibited by etomoxir or enhanced with exogenous carnitine supplements. Transcriptomics of RA blood monocytes and RA-SF macrophages was carried out by microarray.

**Results** We report that hypoxia exacerbates CCL20 and IL-1β release in response to LPS and increases glycolytic intermediates at the expense of carnitines. Modulation of carnitine identified a novel role for FAO in the production of CCL20 in response to LPS. Transcriptomics of RA blood monocytes and RA-SF macrophages revealed that fatty acid metabolism was altered and CCL20 was increased when monocytes enter the RA milieu. In *vitro* analysis of monocytes showed that RA-SF increases carnitine abundance and CCL20 production in hypoxia, which was exacerbated by exogenous carnitine.

**Conclusions** This work has revealed a novel inflammatory mechanism in RA which links FAO to CCL20 production in human monocytes. This may contribute to RA disease pathogenesis by promoting the recruitment of Th17 cells and osteoclastogenesis.² ³

**REFERENCES**


**Disclosure of Interest** None declared.

**P110**

EXPRESSION LEVELS OF MiR-21 AND MiR-29 IN THE SERUM OF SYSTEMIC SCLEROSIS PATIENTS

1R Shumailleva*, 2D Kachakova, 3V Shumailleva-Ivanova, 4P Miteva, 5R Kaneva, 6Z Kolarov, 7S Monov. 1Department of Internal Medicine, Clinic of rheumatology; 2Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University – Sofia; 3Ivva-Bulgaria; 4University Hospital Prof. Ivan Mitev, Medical University – Sofia, Bulgaria


**Career situation of first and presenting author** Assistant. **Introduction** Recent studies reveal the important role of micro-RNAs (miRNAs) in the pathogenesis of systemic sclerosis (SSc). miRNAs are involved in key biological pathways that regulate the fibrotic process in SSc.¹ Deregulated expression of miRNAs has been found in the serum, in skin tissues, in skin fibroblasts as well as in endothelial cells of patients with SSc.²

**Objectives** The aim of our study was to evaluate the expression levels of miR-21 and miR-29 in the serum of SSc patients and to determine their correlation with clinical and immunological parameters.

**Methods** 34 patients fulfilling the ACR/EULAR 2013 classification criteria for SSc were included in the study. miR-21 and miR-29 expression levels in the serum were determined by PCR (SYBR Green technology). 2-ΔΔCt method was used for analysis. 14 healthy donors were used as controls.

**Results** Expression levels of miR-21 were upregulated in the serum of 17 (50.0%) of the patients. The expression of miR-29 was downregulated in 15 (44.12%) of the patients. Receiver operating characteristic (ROC) curve analysis was conducted in order to evaluate the diagnostic accuracy of the expression levels of the studied miRNA in the serum. Area under the curve (AUC) for miR-21 was 0.634 (95% CI=0.479–0.790), p=0.147 with 64.7% sensitivity and 64.3% specificity. AUC for miR-29 was 0.605 (95% CI=0.420–0.790), with 64.3% sensitivity and 52.9% specificity but without statistical significance (p=0.257). The multimarker analysis of the ROC curves for both miRNAs showed AUC=0.714 (95% CI=0.569–0.860), p=0.021 with 79.4% sensitivity and 42.9% specificity. Levels of miR-29 correlated with the levels of miR-21 in the serum (with Spearman correlation coefficient 0.517, p=0.00017) and with the presence of anti-Scl70 antibodies in the serum (with Spearman correlation coefficient 0.438, p=0.010).

**Conclusions** Our data showed a deregulation of miR-21 and miR-29 in the serum of patients with SSc which could suggest their potential role in the disease pathogenesis. Further analysis with higher number of patients is needed to confirm if these miRNAs could be used in the clinical practice as diagnostic biomarkers as well as biomarkers for both disease activity and progression.

**REFERENCES**


**Acknowledgements** The study was supported by Grant 62/2015 funded by Medical University – Sofia, Bulgaria.

**Disclosure of Interest** None declared.

**P110/O18**

EPIGENETIC CHANGES BY INHIBITION OF DOT1L AFFECT WNT SIGNALING, PROLIFERATION AND CELL CYCLE IN DERMAL FIBROBLASTS, WITH NO OVERALL EFFECT ON COLLAGEN DEPOSITION IN MODELS OF FIBROSIS

1N Berghen*, 2J Cremer, 3–4 De Lange, 1–5 Lories. 1Department of Development and Regeneration, KU Leuven; 2Division of Rheumatology, UZ Leuven; 4Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium


**Career situation of first and presenting author** Student for a master or a PhD. **Introduction** The role of epigenetic factors in the pathophysiology of fibrosis, a hallmark of Systemic Sclerosis, is increasingly explored. DOT1L, the unique H3K79-methyltransferase, methylates histone 3 at the Lysine residue at position 79, thereby regulating gene expression programs. In cartilage and bone, DOT1L has cell-type specific effects on Wnt signaling, a pathway suggested to play an important role in fibrosis.

**Objectives** To study the role of DOT1L in fibrosis.

**Methods** Primary human dermal fibroblasts were treated with DOT1L-inhibitor EPZ-5676 or vehicle and stimulated with TGF-β. Expression of smooth muscle alpha 2 actin (ACTA2) and Wnt target genes was measured by RT-qPCR. Western Blot was done for dimethylated H3K79 and β-catenin. Picrosirius Red staining measured collagen deposition. 5-Bromo-2’-deoxy-uridine (BrdU) labeling for proliferation and flow cytometry with Propidium Iodide for cell cycle analysis was done. Col1a2;Cre-ERT²;DOT1L°/°mice, injected...